Abstract: Joint prosthesis (100) with removal device comprising a first portion (10) suitable to be implanted in a bone structure and suitable to couple with a second portion (50), characterised in that said second portion (50) houses within it a removal element (70) suitable to interact with at least one of said first and second portions (10, 50) and in that said removal element (70), is configured to be operated in translation with respect to the second portion (50), and to generate a detachment force such as to uncouple the first portion (10) from the second portion (50) of the joint prosthesis (100).

Abstract: Described herein are methods of modulating autophagic targeting of ferritin in a cell, wherein the method comprises modulating the level and/or activity of nuclear receptor coactivator 4 (NCOA4) in the cell. Also provided are related methods of treatment.

Abstract: Joint prosthesis (100) with removal device comprising a first portion (10) suitable to be implanted in a bone structure and suitable to couple with a second portion (50), characterised in that said second portion (50) houses within it a removal element (70) suitable to interact with at least one of said first and second portions (10, 50) and in that said removal element (70), is configured to be operated in translation with respect to the second portion (50), and to generate a detachment force such as to uncouple the first portion (10) from the second portion (50) of the joint prosthesis (100).

Abstract: Described herein are methods of modulating autophagic targeting of ferritin in a cell, wherein the method comprises modulating the level and/or activity of nuclear receptor coactivator 4 (NCOA4) in the cell. Also provided are related methods of treatment.

Abstract: A novel activating enzyme for ubiquitin, Uba6, is provided. Compositions and methods for inhibiting ubiquitin via the Uba6 pathway are provided. Methods of identifying novel inhibitors of ubiquitination are also provided. Novel RNAi molecules are also provided.

Abstract: A novel activating enzyme for ubiquitin, Uba6, is provided. Compositions and methods for inhibiting ubiquitin via the Uba6 pathway are provided. Methods of identifying novel inhibitors of ubiquitination are also provided. Novel RNAi molecules are also provided.

Abstract: A novel activating enzyme for ubiquitin, Uba6, is provided. Compositions and methods for inhibiting ubiquitin via the Uba6 pathway are provided. Methods of identifying novel inhibitors of ubiquitination are also provided. Novel RNAi molecules are also provided.

Abstract: A novel activating enzyme for ubiquitin, Uba6, is provided. Compositions and methods for inhibiting ubiquitin via the Uba6 pathway are provided. Methods of identifying novel inhibitors of ubiquitination are also provided. Novel RNAi molecules are also provided.

Abstract: A novel activating enzyme for ubiquitin, Uba6, is provided. Compositions and methods for inhibiting ubiquitin via the Uba6 pathway are provided. Methods of identifying novel inhibitors of ubiquitination are also provided. Novel RNAi molecules are also provided.

Abstract: The present invention provides compositions and methods for gene identification, as well as drug discovery and assessment. In particular, the present invention provides components of an E3 complex involved in ubiquitination of cell cycle regulators and other proteins, as well as members of a class of proteins that directly function in recognition of ubiquitination targets. The present invention also provides sequences of multiple F-box proteins.

Abstract: The present invention provides compositions and methods for gene identification, as well as drug discovery and assessment. In particular, the present invention provides components of an E3 complex involved in ubiquitination of cell cycle regulators and other proteins, as well as members of a class of proteins that directly function in recognition of ubiquitination targets. The present invention also provides sequences of multiple F-box proteins.

Abstract: The present invention provides compositions and methods for gene identification, as well as drug discovery and assessment. In particular, the present invention provides components of an E3 complex involved in ubiquitination of cell cycle regulators and other proteins, as well as members of a class of proteins that directly function in recognition of ubiquitination targets. The present invention also provides sequences of multiple F-box proteins.

Abstract: This invention relates to a novel class of heterocyclic compounds useful for selectively inhibiting elastase, selectively inhibiting chymotrypsin-like enzymes, selectively inhibiting trypsin-like enzymes, or for generally inhibiting serine proteases of all classes.

Abstract: Certain novel heterocyclic compounds, their preparation, and their use in inhibiting serine proteases with chymotrypsin-like, elastase-like, and trypsin-like specificity and in the treatment of diseases such as emphysema which involve tissue proteolysis.

Abstract: Certain novel heterocyclic compounds, their preparation, and their use in inhibiting serine proteases with chymotrypsin-like, elastase-like, and trypsin-like specificity and in the treatment of diseases such as emphysema which involve tissue proteolysis.